Form D · Pharmaceuticals

Rapamycin Holdings, Inc.

San Antonio, TX · CIK 0001582949

Offering snapshot reported Jun 18, 2019 · SEC filing

Reported sold
Yet to sell
Offering amount: $7M
Investors reported
0
Form D · investor count
Minimum accepted
$100K
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 18, 2019InitialYet to sellNo comparison0SEC filing
Feb 16, 2018InitialYet to sellNo comparison0SEC filing
Aug 25, 2017InitialYet to sellNo comparison0SEC filing
Apr 18, 2016InitialYet to sellNo comparison0SEC filing
Jul 22, 2014InitialYet to sellNo comparison0SEC filing
Feb 3, 2014Amendment$1,426,094$810,000vs Jul 31, 201318SEC filing
Jul 31, 2013Initial$616,094No comparison8SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-342243
N/A

Source: Form D, filed Jun 18, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Spangler Vaughn Carole Executive
Hargrove Dan Executive
Stephen Dufilho Director
Randy H Goldsmith Director, Executive
Mark Horsey Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
16601 Blanco Rd. Suite #120
San Antonio, TX, 78232